The Frequency of Interval Surveillance in the Adult Hematopoietic Stem Cell Transplant Survivor by Beavers, Jill
Running head:  THE FREQUENCY OF INTERVAL SURVEILLANCE IN THE ADULT 1 
 
 
DNP Final Project   
 
 
 
 
The Frequency of Interval Surveillance in the Adult Hematopoietic Stem Cell Transplant Survivor 
By 
Jill R. Beavers, MS, CCRN, ACNP-BC 
Graduate Program in Nursing 
 
The Ohio State University 
2011 
 
 
 
 
 
DNP Project Committee:  
Jodi McDaniel, PhD, RN, CNP, Committee Chair 
Elizabeth Barker, PhD, RN, CNP, FAANP, FACHE 
Joanne Lester, PhD, RN, CRNP, ANP-BC, AOCN 
Barbara Warren, PhD, RN, CNS-BC, PMH 
 
 
 
Running head:  THE FREQUENCY OF INTERVAL SURVEILLANCE IN THE ADULT 2 
 
 
The Frequency of Interval Surveillance in the Adult Hematopoietic Stem Cell Transplant Survivor 
 
Abstract 
 Cancer treatments for hematologic malignancies can include radiation, chemotherapy, 
immunosuppression, stem cell transplant, and targeted biological therapies.  These therapies can cause 
long-term side effects that may negatively affect quality of life. Many of these late effects are modifiable 
when a proactive systematic plan of prevention and surveillance is implemented. This plan is most 
effective when factors such as past treatments, chromosomal prognostic factors, comorbid health 
conditions, and lifestyle behaviors are considered.  
 A survivorship care plan specific for cancer survivors who have undergone a hematopoietic stem 
cell transplant (HSCT) would enhance the ability of clinicians to monitor for these late effects.  The 
Center for International Blood and Marrow Transplant Research, the European Group for Blood and 
Marrow Transplantation, and the American Society for Blood and Marrow Transplant have recommended 
that a HSCT-specific survivorship care plan include 6-month, 12-month, and annual assessments of 
physical and psychosocial well-being including preventive screenings unique to the HSCT survivor.  
 This quality improvement study described the frequency of documentation of the recommended 
cancer survivorship guidelines by oncology clinicians in the medical records of adult HSCT survivors at 
12 and 24 months post-transplant in one comprehensive cancer center.  This retrospective chart review 
found that only three of the 29 recommended guidelines were documented as being completed in more 
than 50% of the charts at 12 and 24 months.  Furthermore, the data indicated that the remaining indicators 
were documented in less than 50% of the charts at both 12 and 24 months.  These findings were used to 
inform the oncology clinicians of the need for adherence to recommended guidelines and in the planning 
of a hematology and transplant survivorship clinic for individuals who have completed the acute phase of 
their cancer treatment.  
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Chapter One 
Nature of the Project 
The National Cancer Institute (NCI) and Centers for Disease Control (CDC) estimated in 2006 
that approximately 11.4 million people in the United States were living with a history of cancer (National 
Cancer Institute, 2009).  This estimate was 3.5 times higher than in 1971 (National Cancer Institute, 
2009).  Of these 11.4 million, approximately 900,000 were adult survivors of lymphoma, leukemia, and 
myeloma.  While cancer survivors are experiencing extended periods of disease-free or disease-controlled 
states, they are at increased risk for co-morbidities such as liver disease, diabetes, cardiovascular disease, 
osteoporosis, secondary cancers and psychological issues with functional decline (Stull, Snyder, and 
Demark-Wahnefried, 2007).  Cancer survivorship should be celebrated; however, the effects of cancer 
and related treatments on long-term health can be devastating. 
 Cancer treatments for leukemia and lymphoma include radiation, chemotherapy, stem cell 
transplant, and targeted biologic therapies.  Furthermore, high dose and/or prolonged corticosteroids are 
often added to chemotherapy regimens.  While potentially lifesaving, these standard cancer therapies are 
associated with long-term negative health consequences such as liver disease (Rizzo et al., 2006), graft 
versus host disease (Syrjala, Martin, Deeg, & Boeckh, 2007), viral and bacterial infections (Syrjala et al., 
2007), pulmonary disorders (Ravel & Wingard, 2006), secondary malignancies (Ezzone & Beavers, 
2008), cardiovascular disease (Ravel & Wingard, 2006; Majhail et al. 2007), and endocrine disorders 
(Antin, 2002).  Additionally, individuals who have had hematopoietic stem cell transplants (HSCT) are at 
an increased risk for developing cataracts, cognitive changes, neuropathies, osteoporosis, and 
hypertension (Haylock, Mitchell, Cox, Temple, & Curtiss, 2007).  As the length of cancer survivorship 
increases, the long-term side effects of cancer therapies become more evident in the adult HSCT survivor.  
However, studies have demonstrated that many of the late effects of cancer treatments are modifiable 
when a proactive systematic plan of prevention and surveillance is implemented (Haylock et al., 2007).  
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The plan is most effective when factors such as past treatments, chromosomal prognostic factors, 
comorbid health conditions, and lifestyle behaviors are considered (Oeffinger & McCabe, 2006). 
 The American Society of Clinical Oncology (2006) provides cancer survivorship care plans for 
common cancers such as breast, lung and colorectal, but care plans for the HSCT survivor are not 
available.  A survivorship care plan is a record of a patient‟s cancer history and recommendations for 
follow-up care.  It is recommended that HSCT-specific survivorship care plans would include 6-month, 
12-month, and annual assessments of physical and psychosocial well-being with a special emphasis on 
preventative screenings that address the unique needs of the HSCT patient (Stull et al., 2007).  Examples 
of these screenings would include bone densitometry scans for patients who were prescribed steroids for 
more than three months, and pulmonary function tests and mammograms for patients who received 
radiation (Center for International Blood and Marrow Transplant Research, 2007).  
 An effective cancer survivorship plan for the HSCT patient would also monitor for recurrent and 
secondary cancers and provide for coordination of care between primary care and specialty care 
providers.  Early recognition of the potential long-term adverse effects of cancer treatments may improve 
outcomes and quality of life for the HSCT survivor.  The HSCT survivorship care plan would be 
premised on collaboration among multiple disciplines and care settings in the support of the HSCT 
survivor who must navigate from acute inpatient care to subacute outpatient care and finally, to long-term 
chronic care (Beavers & Lester, 2010).  However, because studies have not characterized how oncology 
clinicians use current cancer survivorship guidelines in the HSCT setting, it is necessary to collect 
additional data to identify the potential gaps in survivorship care planning in this unique population.   
Purpose  
 The purpose of this quality improvement doctorate of nursing (DNP) final project was to describe 
existing documentation of cancer survivorship care in the electronic medical records of adult HSCT 
survivors at 12- and 24 months post-transplant in one cancer hospital.  The current recommended 
guidelines from the Center for International Blood and Marrow Transplant (CIBMTR), the European 
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Group for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow 
Transplant (ASBMT) for survivorship care of this population were the standards used to guide the chart 
review process.  The documentation of type and frequency of follow-up care was evaluated to determine 
whether the recommended interventions contained within the guidelines were completed.  
Significance of DNP final project to the healthcare of HSCT cancer survivors 
 Most healthcare providers will likely encounter a HSCT cancer survivor in their practice.  It is 
important for providers to be aware of the potential long-term sequelae of cancer treatments and how to 
effectively manage the health of the HSCT survivors in the post-treatment period.  Studies investigating 
the health and welfare of HSCT patients after cancer treatment have identified numerous physical and 
psychosocial consequences.  For example, Rizzo et al. (2006) noted that HSCT survivors were very 
susceptible to infections, especially if they had experienced chronic graft-versus-host disease.  Therefore, 
the long term goal of this DNP final project was to facilitate survivorship care planning for the HSCT 
survivor by the oncology healthcare team and share the plan with the primary care provider (PCP).   
Active communication among the healthcare team members would potentially improve health outcomes 
for the HSCT survivor.  The survivorship period provides multiple opportunities for healthcare providers 
to improve the health outcomes and quality of life in cancer survivors (Hewitt, Greenfield, & Stovall, 
2006).   
 This DNP final project was significant because the findings revealed that oncology practitioners 
could improve on the frequency and type of their documentation patterns of recommended survivorship 
guidelines containing the 29 surveillance indicators as recommended by the CIBMTR, EBMT, and 
ASBMT.  The 29 indicators address the unique medical and psychosocial needs of HSCT survivors who 
have completed their acute treatment regimen.  These unit-specific adherence data were necessary to the 
planning of a HSCT- specific survivorship care plan.  
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Project Objectives 
Specific aims 
 Primary Aim #1: To describe the frequency of documentation of existing cancer survivorship 
guidelines at 12 to 24 months post-transplant in the charts of adult HSCT survivors by oncologists and 
nurse practitioners.  
 Primary Aim #2:  To describe the prescribing patterns of oncologist and nurse practitioners in the 
provision of survivorship care in the adult HSCT survivor.  
Hypotheses 
 Hypothesis #1:  Survivorship care in accordance with the 29 evidenced-based indicators included 
in the cancer survivorship guidelines will be documented in less than 50% of the charts of adult HSCT 
survivors.  
 Hypothesis #2:  Prescribing patterns for tests within the 29 indicators for surveillance and 
symptom management in the adult HSCT survivor will be implemented in less than 50% of the charts.  
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Chapter 2   
Review of Literature 
Theoretical Framework: Shared Care Model 
 The shared care model is a theoretical framework that supports the long-term care of cancer 
survivors and the implementation of survivorship care plans.  Shared care refers to the care of a patient 
that is shared by two or more providers of different specialties with the provision of comprehensive care 
(Orton, 1995).  The underlying concepts of shared care include personal communication and periodic 
transfer of knowledge between the specialist and the PCP (Oeffinger & McCabe, 2006).  Typically, 
cancer patients are guided into the cancer trajectory by their PCP.  Once diagnosed with cancer, the care 
swiftly transfers from the PCP to the oncology team.  In the case of a patient undergoing HSCT, the care 
may remain with the oncology team for several months.  Following the acute phase of stem cell 
transplantation, the HSCT patient is typically referred back to their PCP.  As a result, the PCP may be 
more likely to identify and treat chronic conditions such as graft-versus-host disease.  HSCT survivors 
can also develop secondary health issues that may or may not be related to their cancer treatment, yet 
require ongoing management by the PCP.  
 The shared care model can guide survivorship care planning for long-term follow-up of HSCT 
survivors. The model (Figure 1) developed by Oeffinger and McCabe (2006) illustrates ongoing 
communication between the oncologist and the PCP.  Communication point „a‟ in the model refers to the 
oncologist and the PCP.  This communication should include information about the cancer diagnosis, 
staging, grading, past treatment regimens and future treatment plans.  In the majority of cases, the PCP 
would continue to treat the patient‟s comorbid conditions and provide routine health maintenance.   
 When considering the HSCT survivor, the PCP would begin seeing the patient in routine follow-
up after the HSCT survivor has completed the early survivorship phase of their care. The responsibility of 
the PCP would be to ensure that the emotional and physical needs of the patient are met.  The PCP could 
consult with the oncology team whenever necessary and refer the patient back to the oncology team for 
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specific problems and periodic evaluations.  A copy of the patient‟s survivorship care plan and treatment 
summary would be given to the PCP to assist in monitoring the long-term care of the HSCT survivor.  
Periodic communication between the oncologist and PCP would be an expectation to ensure that there 
was consistency of care.  
 A three-year follow-up study by Blaauwbroek, Tuinier, Meyboom-de Jong, Kamps, and Postma 
(2008) assessed the feasibility of shared care between pediatric oncologists and family physicians in the 
long-term follow-up of survivors of childhood cancers.  Opinions about the shared care model by 
survivors and family physicians were also evaluated.  The study noted that 89 of the 101 (88%) survivors 
were satisfied with the shared care model; 94 of 115 (82%) of the family physicians were satisfied.  The 
shared care model has demonstrated improved patient outcomes in the management of patients with 
various chronic diseases including diabetes, chronic kidney disease and those patients who receive oral 
anticoagulant therapy (Oeffinger & McCabe, 2006).  
 Over time, the incidence of long-term treatment effects experienced by survivors of HSCT may 
increase as their anticipated length of life increases.  With scheduled long-term follow-up, certain late 
effects may be identified at an earlier, more treatable state.  Earle and Neville (2004) reported that five-
year survivors of colorectal cancer who were followed by an oncologist and PCP were more likely to 
receive the recommended follow-up care in comparison with survivors who were seen by just one 
physician type.  To date, there have been no published data from a U.S. study evaluating the shared care 
model for cancer survivors.       
Related research   
 The related research studies that were reviewed prior to implementing the current project were 
selected through PubMed and MEDLINE searches using the specific search term “cancer survivor” as 
well as cross-referenced medical subject heading terms such as “survivors,” “care plan,” “long-term 
follow-up,” “cancer guidelines,” “bone marrow transplant,” “stem cell transplant,” “quality of life, “and 
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“complications.”  Although all articles from 1995 to 2010 were considered, the search was limited to 
articles in the English language; over 75 articles and books were reviewed.   
 Previous studies document that the HSCT survivor has an increased risk of premature mortality, 
morbidity, and adverse health events that vary according to the treatment regimen (Syrjala et al., 2007). 
For example, patients who have undergone a HSCT are at risk for developing liver disease (Strasser et al. 
1999), graft versus host disease (Syrjala et al., 2007), viral and bacterial infections (Rizzo et al., 2006), 
pulmonary disorders (Ravel & Wingard, 2006), secondary malignancy (Ezzone & Beavers, 2008), 
cardiovascular disease (Majhail et al. 2007), and endocrine disorders (Antin, 2002). 
Liver disease  
 Liver disease is commonly found in HSCT survivors.  Strasser et al. (1999) discussed the 
multiple potential liver conditions that can occur after HSCT, including liver cirrhosis, veno-occlusive 
disease, and chronic graft versus host disease of the liver.  Liver cirrhosis is prevalent in long-term stem 
cell transplant survivors.  Of the 3,721 patients who survived one or more years after HSCT, 31 patients 
had clinical or histological evidence of cirrhosis.  Of the 1,850 patients who had survived five or more 
years, 23 patients had evidence of cirrhosis; of the 860 patients who survived 10 or more years from 
transplantation, 19 were diagnosed with cirrhosis.  Of interest, 48% of the patients who developed 
cirrhosis died at a median of five years after HSCT.  The most common factor related to the development 
of cirrhosis was the presence of chronic viral hepatitis.  
Hepatic veno-occlusive disease, also known as sinusoidal obstructive syndrome (SOS), is another 
serious potential complication of HSCT.  The clinical features of SOS include hyperbilirubinemia, fluid 
retention, and painful hepatomegaly.  While liver dysfunction with accompanying jaundice is common 
after HSCT, patients with SOS exhibit symptoms of circulatory interference that precedes abnormal liver 
tests.  Patients who receive a myeloablative conditioning regimen prior to HSCT are at increased risk for 
SOS.  Patients who undergo a myeloablative conditioning regimen that includes high dose chemotherapy 
with cyclophosphamide (120mg/kg) plus total-body irradiation have a higher risk of developing SOS 
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(DeLeve, 2003).  Treatment for SOS consists of supportive care including management of volume status, 
monitoring of multisystem organ failure, and possible hemodialysis and mechanical ventilation. 
Graft versus host disease 
Graft versus host disease (GVHD) is another potential long-term side effect in patients who 
undergo HSCT.  GVHD occurs when donor T cells recognize major or minor histocompatibility antigens 
and the T cells become activated and subsequently attack the organs.  Symptoms of GVHD are variable 
but frequently involve the collagen portions of the skin, liver, eyes, mouth, sinuses, and esophagus.      
The skin, gastrointestinal system, and eyes are the most common body systems that are affected by 
GVHD.  GVHD is considered acute if it occurs within the first 100 days after transplant, or chronic if it 
occurs 100 days after transplant.  Left uncontrolled, GVHD interferes with immune reconstitution and is 
strongly associated with increased risk of opportunistic infections (Syrjala et al., 2007).  
Studies have identified risk factors for the development of chronic GVHD (Vogelsang, 2001).  
Five-year survival rates for patients with high-risk chronic GVHD are approximately 40% to 50%.  Only 
50% of patients with chronic GVHD are able to discontinue immunosuppression within five years of 
diagnosis.  The remaining 40% die or develop recurrent malignancy before the GVHD resolves.  Ongoing 
treatment with high-dose glucocorticoids causes significant morbidity, which often leads to additional 
medical therapies to decrease the dependence on steroids for controlling the disease (Lee, Vogelsang, & 
Flowers, 2003).   
Viral and bacterial infections 
Rizzo, et al., (2006) reported that all HSCT survivors are susceptible to infections, but that 
infections may be more prevalent in survivors who develop GVHD.  Immunization with pneumococcal 
vaccines does not provide complete protection against these bacterial infections; therefore, antibacterial 
prophylaxis is also recommended, especially in patients with GVHD (Rizzo, et al., Syrjala, et al., 2007).  
Viral-induced infections occur commonly in the HSCT patient, especially infections from varicella-zoster 
virus (VZV) or cytomegalovirus (CMV) and may cause considerable complications (Syrjala, et al., 2007).  
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Fungal infections with late invasive aspergillosis can also occur with devastating outcomes that include 
lifelong pulmonary dysfunction, chronic obstructive pulmonary disease and possibly death.  Drug-
induced immunosuppression complicated by high-dose steroid use can increase the frequency, morbidity, 
and mortality from these infections (Syrjala, et al., 2007). 
Pulmonary complications 
 Diffuse alveolar hemorrhage is a potential complication of HSCT that may occur up to four 
weeks after transplant (Ravel & Wingard, 2006).  Symptoms and complications of this condition include 
dyspnea, hemoptysis, hypoxemia, decreased hematocrit, diffuse chest infiltrates, an increased alveolar-
arterial gradient, and restrictive ventilatory defects.  Diffuse alveolar hemorrhage is treated with high dose 
corticosteroids which can suppress the patient‟s immune system and cause the patient to be at risk for 
opportunistic infection (Ravel & Wingard, 2006).  
 Patients who have had HSCT are also at increased risk of developing bronchiolitis obliterans 
organizing pneumonia (BOOP) (Ravel &Wingard, 2006).  Advanced disease and the presence of GVHD 
are associated with a higher risk of developing this complication.  The collective incidence of BOOP two 
years after an unrelated donor HSCT was lower in patients who received a reduced-intensity conditioning 
regimen (fludarabine, busulphan and/or cladribine) compared with patients who received a myeloablative 
conditioning regimen (busulphan, total-body irradiation, and/or cyclophosphamide), with rates of 17% 
compared to 2.3% (Ravel & Wingard, 2006).  
Secondary malignancy 
 Secondary malignancies are also common in HSCT survivors.  One example of a common 
secondary malignancy is post- transplant lymphoproliferative disorder (PTLD).  PTLD is a potential 
complication that involves an abnormal growth of lymphocytes.  This lymphocyte growth may be 
inflammatory or neoplastic (Ezzone & Beavers, 2008).  Most PTLDs arise from B-cell proliferation 
induced by infection with the Epstein-Barr virus (EBV) in the chronically immunosuppressed patient.  
Since 1968, EBV has been known to cause infectious mononucleosis and has been associated with non-
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Hodgkin‟s lymphoma and oral hairy cell leukoplakia.  The EBV genome is found in more than 90% of B-
cell PTLD occurring in the first year after HSCT.  In a patient who has had HSCT, the EBV may activate 
proliferation of B lymphocytes leading to an overgrowth of hyperplastic, polyclonal lesions occurring 
early after transplant (Knowles, Cesarman, & Chadburn, 1995). 
Cardiovascular disease 
 Cardiac abnormalities are commonly related to the preparation regimen before HSCT. 
Anthracycline therapy at doses greater than 300 mg/m
2
, ablative dose cyclophosphamide greater than 150 
mg/kg, chest radiation therapy, total body irradiation, and high-dose corticosteroids increase a patient‟s 
risk of developing congestive heart failure (Ravel & Wingard, 2006; Majhail et al. 2007).  Many HSCT 
patients have cardiac dysfunction during and immediately after transplant and as many as 50% of HSCT 
survivors have persistent abnormalities manifesting as congestive heart failure, exercise-induced 
shortness of breath, and blood clots in the extremities (Majhail et al. 2007). 
Endocrine dysfunction 
 Endocrine dysfunction is also common after HSCT and can occur in up to 25% of adults (Ravel 
& Wingard, 2006).  Total body irradiation places the adult HSCT survivor at risk for gonadal dysfunction 
(Antin 2002) and a multitude of thyroid disorders.   
Gonadal failure can result from high-dose alkylating agents or total body irradiation.  The 
severity of failure depends on the dose of radiation.  Post pubertal female patients can experience ovarian 
failure which increases the risk of early osteoporosis, bone fractures, lipid metabolism disorders, and 
atherosclerotic heart disease (Ravel & Wingard, 2006).  
 Compensated hypothyroidism and euthyroid sick syndrome, which is low free triiodothyronine, 
free thyroxine, or both, along with normal or low thyroid-stimulating hormone are the most frequent 
thyroid abnormalities after HSCT (Toubert et al., 1997).  The threat of hypothyroidism is increased in 
patients who receive irradiation of the head and/or neck (Boulad et al., 1995).  HSCT survivors who have 
been diagnosed with hypothyroidism will require lifelong thyroid replacement therapy.  A study of 72 
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HSCT survivors revealed that 6% of male patients and 5% of female patients had overt hypothyroidism 
(Ravel & Wingard, 2006).  All HSCT survivors who have received irradiation should have their thyroid 
function studies evaluated annually.  
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Chapter 3  
Methods 
Research Design 
 This DNP final project used a descriptive design involving retrospective chart reviews. The 
electronic medical records of adult HSCT patients from one Midwest cancer center were reviewed for 29 
indicators in 10 categories of long-term cancer survivorship follow-up at 12 to 24 months.  A convenience 
sample of autologous and allogeneic stem cell survivors was identified from the Bone Marrow Transplant 
Unit database which provides data about primary disease, type and date of transplant.  All eligible HSCT 
survivors at least 24 months from date of transplant were considered for inclusion in the DNP final 
project.  Furthermore, adult HSCT survivors from all seven oncology clinicians‟ practices were eligible 
for the study.  An exemption for informed consent was obtained as this was a retrospective chart review 
of existing data from electronic medical records. 
Sample 
 Inclusion criteria 
 Autologous or allogeneic hematopoietic stem cell transplant (HSCT) survivor 
 ≥ 18 years of age 
 At least 730 days status post HSCT 
 Primary diagnosis of acute leukemia, lymphomas, myelomas, myelodysplastic syndrome 
and/or myelofibrosis.  
 Exclusion criteria 
 Those patients less than 730 days post HSCT 
 Patients with a primary diagnosis of aplastic anemia and/or multiple sclerosis 
 Survivors not receiving at least 24 months of follow-up care in the HSCT clinic 
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Methods 
The medical records of all eligible autologous and allogeneic HSCT survivors were reviewed at 12- 
and 24-months status post HSCT.  Documentation of the ten categories, as based on the Joint 
Recommendations of the EBMT, ASBMT, and the CIBMTR (CIBMTR, 2006) were observed at 12 and 
24 months post transplant.  The 29 indicators contained within the ten categories that were tracked in this 
retrospective chart review included:   
 Liver function, including serum liver panel and ferritin 
 Blood pressure monitoring, heart rate, echocardiogram, chest x-ray, smoking habits/cessation, 
and pulmonary function studies 
 Kidney function, including serum levels of  BUN, creatinine, and protein  
 Musculoskeletal symptoms such as muscular strength/weakness, muscular atrophy, bone density 
 Endocrine and fertility issues, including menstruation, serum (male/female) hormone levels, 
libido, expressed desire for parenthood, erectile dysfunction 
 Infectious disease prophylaxis, including vaccinations such as influenza, pneumococcal, hepatitis, 
tetanus, cytomegalovirus, pneumocystis carinii pneumonia prophylaxis. 
 Healthy lifestyle, including dietary habits/restrictions, exercise regimen, and routine screening for 
secondary cancers 
 Emotional health, including psychosocial symptoms, coping mechanisms, counseling referrals, 
sexual function assessment  
 Dental health, including annual dental exams 
 Vision screening, including annual vision exam, pain and dryness 
 Documentation of prescribing patterns at 0 to 24 months was reviewed to determine if appropriate 
screening and survivorship follow-up interventions were performed.  These included documentation of 
appropriate serum and radiographic studies, healthy lifestyle measures, cancer screenings, psychological 
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assessments, and vaccinations.  Additionally, potential negative outcomes of these interventions as related 
to omission of recommended long-term survivorship care were reviewed.    
Sample size estimation 
 The Bone Marrow Transplant Unit at this Midwestern cancer hospital provides care for 
approximately 200 autologous and allogeneic HSCT patients per year.  It was recommended that 385 
charts be reviewed in order to obtain a 95% confidence interval with a margin of error less than 5% 
surrounding the fraction of charts completed (Stommel & Wills, 2004). 
Instruments 
 Data were collected from electronic medical records (EMR) using two separate EMR systems. 
The first system, TransChart, contained medical information documented by the outpatient hematological 
transplant clinic from September 2006 through July 2009.  The second and current system, Integrated 
Health Information System (IHIS), provided data from July 2009 to present.  These retrospective chart 
reviews provided data relevant to oncology clinician documentation of the 29 indicators at 12- and 24-
months; clinicians included advanced practice nurses (APNs), and physicians.   
 Patients were assigned an identification number, i.e. HSCT 01, HSCT 02, etc., in order to 
maintain confidentiality.  Data were collected by members of the research team and documented on a 
Microsoft Excel (2007) spreadsheet.  Available data were recorded and when information was not 
available, the data field was marked not applicable.  Abstracted data were stored in a locked cabinet in a 
locked office to protect confidentiality.  
Data collection was confined to the listed investigators to provide for inter-rater reliability.  The 
lead NP reviewed the first 30 charts completed by every member of the research team so that inter-rater 
reliability could be assessed.  When the inter-rater reliability co-efficient between the NP and the research 
team member was found to be unacceptable (r < 0.90), the NP provided appropriate education and 
clarification for the reviewer, after which inter-rater reliability was reassessed.  
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Data Analysis 
 Data were imported into Statistical Package for the Social Sciences (SPSS), Version 19.0.  
Primary Aim #1:  To describe the frequency of documentation of cancer survivorship guidelines at 12 to 
24 months post-transplant in the adult HSCT survivor by oncology clinicians. 
 Data were analyzed for the practitioner adherence to the 29 indicators at 12- and 24-months.  One 
sample tests of proportions were used to test whether adherence was less than 50%.  A Chi-square test 
was used to compare the frequency of long-term follow-up recommendations that were documented 
across the recommended 29 indicators.  Appropriate post-hoc Chi-square tests were used to test for 
differences between pairs of indicators.    
Primary Aim #2: To describe the prescribing patterns of oncology clinicians in the provision of 
survivorship care in the adult HSCT survivor.  Data analysis has not been completed. 
Compliance to the DNP essentials 
 The third DNP essential describes clinical scholarship and analytical methods for evidence-based 
practice.  This project was a retrospective descriptive analysis of specific outcomes related to HSCT 
survivorship care.  The hypothesis that survivorship care for adult HSCT survivors would be documented 
in < 50% of the charts reviewed represents the paradigm of scholars giving meaning to isolated 
phenomena.  To my knowledge this is the first DNP final project at a comprehensive cancer center to 
explore the frequency of adherence to recommended evidenced-based guidelines that have been 
developed to guide the care of HSCT survivors in the post-hematopoietic transplant period.   
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Chapter 4 
 Findings 
Data retrieval  
          The data were collected via a chart review process that was an interdisciplinary endeavor by three 
registered nurses (RN) and a clinical researcher/NP; all four nurses had been employed in the hematology 
and transplant clinic for at least one year.  Data collection began in September 2010 and was completed 
within four months.  The 385 charts identified for review were accessed from two different electronic 
medical records, TransChart and IHIS, which provided data over the intended time period. 
The first 30 charts that each RN reviewed were also reviewed by the lead NP to assess inter-rater 
reliability.  It was determined that Cronbach‟s alpha was < 0.90.  Therefore each RN received additional 
instruction from the lead NP regarding the existing cancer survivorship guidelines for autologous and 
allogeneic stem cell transplant survivors.  The lead NP clarified the meaning of each categorical item with 
each RN prior to additional extraction of data.  For example, unlike allogeneic stem cell transplant 
survivors who are required to have cytomegalovirus (CMV) testing done at 12 months and annually, 
autologous stem cell transplant survivors are not required to have CMV testing and therefore should not 
be marked „deficient‟ in their long-term follow-up.  For this type of patient, “not applicable” was placed 
on the data collection sheet.  Following the brief instructions, inter-rater reliability was again calculated 
for each RN/NP after the review of 30 additional charts using Cronbach‟s alpha and deemed satisfactory 
(r > 0.90).  
 During the process of inter-rater reliability testing it was discovered that the indicator „risk for 
cardiovascular disease‟ was essentially documented twice because „smoking cessation‟ and/or „aggressive 
management of blood pressure‟ provided proxy measures for „risk for cardiovascular disease‟.  This 
finding indicated a potential duplication of data among the combined indicators as provided by ASMT, 
EBMT, and CIBMTR guidelines.  Therefore, the indicator of „risk for cardiovascular disease‟ was 
deleted; „smoking cessation‟ and „aggressive management of blood pressure‟ were retained.  
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Results 
 A total of 385 charts of HSCT survivors were reviewed to determine if evidence-based indicators 
were implemented at 12 and 24 months post-transplant in at least 50% of the charts in the adult HSCT 
survivor sample.  The sample included the following diagnoses: 102 (26%) leukemia, 154 (40%) multiple 
myeloma, 83 (22%) non-Hodgkin‟s lymphoma, and 41 (11%) Hodgkin‟s lymphoma and 5 (1%) 
myelodysplastic syndrome (Table 1).  A total of 84 (22%) patients were evaluated only at 12 months, and 
not at 24 months due to loss to follow-up or death.  Therefore, a total of 301 charts were subsequently 
reviewed for documentation of the evidenced-based indicators of long-term follow-up at 12 and 24 
months post HSCT by oncology clinicians.  
 The Clopper-Pearson interval test was used to calculate binomial confidence intervals.  A 
binomial confidence interval relies on the assumption of a binomial distribution (Stommel & Wills, 
2004).  A binomial distribution applies in this data analysis because each trial of the variable had two 
possible outcomes: either the recommended guideline was followed, or the recommended guideline was 
not followed.  The confidence interval chosen for this project was 95% with a margin of error less than 
5% surrounding the fraction of the charts completed 
Data analyses 
 The review consisted of the RNs documenting adherence to 10 health categories containing a 
total of 29 evidenced-based indicators (Figure 2).  The hypothesis was that these evidenced-based 
indicators would be documented as completed in less than 50% of the charts for each of the 29 indicators 
at 12 and 24 months.  Of the 29 indicators, only three were documented as being completed in greater 
than 50% of the charts (Table 2). These three indicators included aggressive management of blood 
pressure, serum blood urea nitrogen (BUN) and creatinine and serum liver function testing (LFT).  Blood 
pressure was managed aggressively in 60.2% of the charts at 12 months and in 57.7% of the charts at 24 
months.  Serum BUN and creatinine were obtained in73.2% of the charts at 12 months and in 71.2% of 
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the charts at 24 months.  Serum LFTs were obtained in 71.4% of the charts at 12 months and in 69.6% of 
the charts at 24 months (Table 2).  
 There were two additional indicators which were documented as completed in more than 50% of 
the charts at 12 months, but in less than 50% of the charts at 24 months.  These were „consideration of 
herpes simplex virus and antifungal prophylaxis‟ and „pneumocystis carinii pneumonia (PCP) 
prophylaxis‟.  At 12 months, these were provided in 60.2% and 60.5% of the charts, respectively and in 
43.4% and in 46.1% of the charts, respectively, at 24 months (Table 3). 
 The remaining 24 indicators were documented as completed in less than 50% of the charts.  
Cytomegalovirus (CMV) testing was documented as completed in 47.7% of the charts at 12 months and 
in 43.0% of the charts at 24 months.  Female sex hormone levels were documented as completed in 3.8% 
of the charts at 12 months and in 4.0% of the charts at 24 months.  Serum levels of male sex hormones 
were documented as completed in 25.4% of the charts at 12 months and in 17.7% of the charts at 24 
months.  Serum ferritin levels were documented as completed in 7.0% of the charts at 12 months and in 
9.2% of the charts at 24 months.  Finally, thyroid function assessment was documented as completed in 
24.5% of the charts at 12 months and in 24.9% of the charts at 24 months (Table 4).  
 Imaging studies were also documented as completed in less than 50% of the charts.  Bone 
densitometry testing was documented as completed in 10. 8% of the charts at 12 months and in 9.8% of 
the charts at 24 months.  Chest radiography was documented as completed in 26.3% of the charts at 12 
months and in 20.1% of the charts at 24 months.  Mammograms were documented as completed in 5.8% 
of the charts at 12 months and 5.9% of the charts at 24 months.  Pulmonary function tests (PFT) were 
documented as completed in 23.4% of the charts at 12 months and in 19.2% of the charts at 24 months 
(Table 5).  
 Preventive exams and screenings were documented as completed in less than 50% of the charts as 
were education concerning breast, skin, and/or testes self exam.  These interventions were documented as 
completed in 0.5% of the charts at 12 months and in 1.6% of the charts at 24 months.  Endocarditis 
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prophylaxis was documented as completed in 2.0% of the charts at 12 months and in 1.1% at 24 months.  
Osteopenia prophylaxis with bisphosphonates was documented as completed in 23.0% of the charts at 12 
months and in 23.8% at 24 months.  Papanicolaou (PAP) tests were documented as completed in 2.7% of 
the charts at 12 months and in 2.1% at 24 months.  
Regular dental exams were documented as completed in 1.8% of the charts at 12 months and in 
1.9% at 24 months.  Routine vision exams were documented as completed in 5.7% of the charts at 12 
months and in 5.2% at 24 months.  Schirmer testing was documented as completed in 29.2% of the charts 
at 12 months and in 31.8% at 24 months.  Screening for steroid myopathy was documented as completed 
in16.8% of the charts at 12 months and in 12.6% at 24 months.  Secondary cancer screenings were 
documented as completed in 3.9% of the charts at 12 months and in 4.1% at 24 months.  Smoking 
cessation was documented as completed in 32.3% of the charts at 12 months and in 34.2% at 24 months.  
Vaccinations were documented as completed in 7.6% of the charts at 12 months and in 6.8% at 24 months 
(Table 6).  Psychosocial support recommendations were documented as completed in less than less than 
50% of the charts.  These recommendations included emotional health counseling, (10.6% at 12 months 
and 8.7% at 24 months), sexual function assessment (1.0% at 12 months and 0.5% at 24 months), and use 
or the offer of support groups (1.3% at 12 months and 1.1% at 24 months) (Table 7). 
Compliance to the DNP essentials 
 The second DNP essential describes organizational and systems leadership for quality 
improvement and systems thinking.  This quality improvement project will improve patient and 
healthcare outcomes because it described the frequency of documentation of cancer survivorship 
guidelines at 12- and 24- months post-transplant in the adult HSCT survivor by oncologists and advanced 
practice nurses.  These results were then analyzed and changes implemented based on study findings.    
 One quality improvement initiative that was a direct result of the study findings was the 
assessment of HSCT survivors‟ vaccination status.  The omission of this important indicator was 
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identified early in the chart review process.  The issue was quickly resolved with collaborative efforts 
among the oncology clinicians in the outpatient hematology clinic.   
 The sixth DNP essential describes interprofessional collaboration for improving patient and 
population health outcomes.  This essential was integrated into the project by having three registered 
nurses and a clinical researcher/NP perform data collection.   
 
Discussion 
Interpretation of data 
 The DNP final project data demonstrated that several components of the cancer survivorship 
guidelines as proposed by ASBMT, EBMT, and CIBMTR were not documented at 12 to 24 months post- 
hematopoietic stem cell transplant in the charts of adult HSCT survivors by oncologists and NPs in a 
Midwest cancer hospital.  These findings suggest that the various health-related and preventive care 
interventions were not performed, or if completed were not documented in a manner that supports 
interdisciplinary communication.  This apparent lack of long-term follow-up care may contribute to 
poorer health outcomes and unmet psychosocial needs of HSCT survivors.  
 A significant finding that emerged early in the chart review process was the frequent absence of 
documentation regarding revaccination of hemophilus influenza b, tetanus-diphtheria toxoid, inactivated 
polio, Hepatitis B, and if indicated, measles, mumps, and rubella (Johnston & Conly, 2002).  
Revaccination of the HSCT survivor is an indicator in the survivorship guidelines and an essential 
component of preventive health care as chemotherapy and radiation treatments ablate the HSCT 
survivor‟s immune system.  Therefore, prevention of infection is vital to the long-term health of the 
HSCT survivor (Syrjala et al., 2007).  This information was immediately shared with the RNs, NPs, and 
physicians in the hematology clinic and a system was developed to ensure appropriate and timely 
vaccinations.   
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 Additional data generated from the chart review process revealed that only three of the 29 
indicators in the cancer survivorship guidelines were documented as completed in more than 50% of the 
charts at 12 and 24 months post-HSCT, consistent with the DNP final project hypothesis #1: survivorship 
care in accordance with evidenced-based indicators would be documented in less than 50% of the charts 
for each of the 29 indicators for the adult HSCT survivor.  These three indicators included aggressive 
management of blood pressure, serum liver function tests, and serum blood urea nitrogen and creatinine 
(Table 3).  Two additional indicators, prophylaxis of herpes simplex and fungal infection and prophylaxis 
against pneumocystis carinii pneumonia (Table 4) were documented in more than 50% of the charts at 12 
months, but in less than 50% at 24 months.  Importantly, the remaining 25 indicators were documented in 
less than 50% of the charts at both 12 and 24 months.  These indicators included cytomegalovirus, male 
and female sex hormone levels, serum ferritin, thyroid function tests, urine protein (Table 5), bone density 
testing, chest radiograph, mammograms, pulmonary function tests (Table 6), breast, skin, and/or testes 
self-exam, endocarditis prophylaxis, osteopenia prophylaxis, PAP smear, regular dental and vision exams, 
and Schirmer testing, screening for steroid myopathy, secondary cancer screenings, smoking cessation, 
and vaccinations (Table 7), emotional health counseling, sexual function assessment, and support groups 
(Table 8). 
 To my knowledge this is the first DNP final project at a comprehensive cancer center to explore 
the frequency of documentation of the recommended evidenced-based guidelines by oncology clinicians 
that have been developed to guide the care of HSCT survivors in the post-hematopoietic transplant period.  
It remains unknown if certain measures were completed but not documented by this institution‟s blood 
and marrow transplant (BMT) team at 12 and 24 months.  Likewise, it is unknown if 12- and 24-month 
indicators were fulfilled by the survivors‟ PCP which could narrow perceived gaps in care.  These issues 
are important to consider as clinicians prepare for the provision of formal survivorship care, specifically 
in regard to the shared care model.  
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Integration of findings 
 The DNP final project findings confirmed the hypothesis that long-term survivorship care 
planning was sub-optimal (<50%) in this institution‟s HSCT population.  Prior to initiating a formal 
survivorship care clinic for HSCT survivors, a professional educational plan was developed by the lead 
NP.  She attended the George Washington University‟s Executive Training Conference on Navigation and 
Survivorship in Washington, D.C.  This intensive, two-day executive training program provided program 
leaders with the tools and resources needed to launch and sustain navigation and survivorship programs. 
Attendees were taught elements of business planning as well as internal and external environmental 
analyses.   
 A preliminary step in the initiation of the survivorship clinic involved the organization of a 
HSCT-specific survivorship task force.  This committee convened in September 2010 and was charged 
with decision-making aspects of an institutionally based HSCT survivorship care program.  Membership 
was open; an interdisciplinary team was formed consisting of housekeepers, lab technicians, massage 
therapists, RNs, NPs, discharge planners, physicians, and the chief nursing officer.  The team met at six 
week intervals.  The agenda for the first meeting included a review of short-term and long-term goals, a 
review of treatment summary templates that were available online and at other cancer centers, and a 
group discussion.  Tasks were assigned and timelines generated.  Over the course of several months the 
task force achieved many of their primary goals.  The most significant goal was to create a computerized 
template to remind BMT providers which surveillance screening tests were required at specific time 
points.  This was accomplished by creating a “best practice” list (Figure 3) based on the recommended 
guidelines from the ASBMT, EBMT, and CIBMTR (2006).  When using the best practice list, the 
interdisciplinary team learned that survivorship care of the HSCT survivor was more than just an 
evaluation of the patient‟s hematologic disease status.  The need for a designated outpatient HCST 
survivorship visit was quickly recognized.    
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 The Hematology and Transplant Survivorship Clinic (also known as the survivorship clinic) that 
is now in operation is conducted by the NP one day per week.  HSCT survivors can expect to spend 60-90 
minutes with the NP to review their treatment summary for completeness and accuracy (Figure 4) and to 
discuss the recommended follow-up care regarding surveillance indicators (Figure 5), cancer screenings 
(Figures 6 and 7), and any psychosocial needs.  Referrals, if needed, are then arranged.  A print copy of 
the completed treatment summary and recommended follow-up care plan is given to the HSCT survivor 
and an electronic copy is sent to their referring hematologist, PCP, and local hematologist, if applicable.  
 To date, 12 allogeneic HSCT survivors have been evaluated in the survivorship clinic.  The 
majority of patients have requested additional psychosocial services, such as counseling to help them 
understand their „new normal‟.  Many patients have complained of sexual dysfunction issues and 
decreased libido.  The survivorship clinic is currently examining options to assist survivors with these 
concerns.  
Compliance to the DNP essentials 
 The fourth DNP essential describes information systems/technology and patient care technology 
for the improvement and transformation of health care.  As a result of this DNP final project, 
computerized templates for treatment summaries and survivorship care plans have been developed.  These 
computerized templates were developed as a Microsoft Word® document and then imported into the IHIS 
system as a user-friendly smart phrase.  These smart phrases are available to anyone and are easily 
modifiable.  
 The seventh DNP essential describes clinical prevention and population health for improving the 
nation‟s health.  This essential was incorporated into the DNP final project in several ways : (1) 
development of computerized templates for the HSCT survivor, (2)improvement in administration and 
documentation of vaccination status in the HSCT survivor.  Both of these outcomes focus on health 
promotion and disease prevention.   
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Conclusion 
 The data from this DNP final project revealed the absence of several important recommended 
indicators of long-term survivorship care planning in the charts of HSCT survivors.  One of these 
indicators, revaccination of the HSCT survivor, was swiftly implemented by the BMT team, while the 
remaining indicators will be implemented over time.  The findings from this DNP final project will guide 
the further development of survivorship care for the HSCT in this Midwest cancer hospital.    
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Chapter 5 
Summary 
 Standard cancer treatment for leukemia and lymphoma patients includes radiation, chemotherapy, 
and steroids.  These interventions are often associated with long-term negative health consequences such 
as cataracts, cognitive changes, neuropathies, osteoporosis, and hypertension (Haylock, Mitchell, Cox, 
Temple, and Curtiss, 2007).  As the length of cancer survivorship increases, the long-term effects of 
standard cancer therapies become more evident.   
 Bone marrow transplant is an effective therapy for the treatment of hematologic malignancies 
such as leukemia and lymphoma.  However, the negative health consequences associated with these 
intense interventions create new challenges for the provider and the survivor.  HSCT survivors are at 
increased risk for developing secondary cancers, other physical side-effects and psychosocial issues.  
Therefore, it is vital that the clinicians who care for the HSCT survivor understand the unique needs of 
this population, their families, and groups affected by these diseases.  A proposed survivorship care plan 
including standard screening schedules and a long-term follow-up survivorship clinic could improve the 
quality of life for HSCT survivors.   
Limitations 
 One limitation to this DNP final project involves the possibility that despite the lack of 
documentation in the sample of charts reviewed, an intervention may have been completed.  For example, 
HSCT survivorship patients may have received their immunizations or other routine follow-up tests 
without documentation, or at other facilities; therefore the event may or may not have been appropriately 
documented in the TransChart or IHIS systems.  Improved communication within and between medical 
systems is necessary to narrow these gaps in care.  The survivorship care plan is intended to provide a 
mechanism to enhance shared care between providers and provide documentation of received care and 
ongoing long-term care needs.  
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Implications for practice 
 The data generated from this DNP final project were used to develop a computer-based 
survivorship care plan for the HSCT patient and establish a survivorship clinic in a Midwest 
comprehensive cancer center.  The data also provided the basis for ongoing discussions among healthcare 
providers about the beneficial effects of survivorship care planning and the promotion of healthy 
outcomes for HSCT survivors.  As a result, healthcare providers have begun to contribute ideas for 
refining aspects of the HSCT survivorship care plan.  
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Table 1 
Percentage of Distribution of Cancer Types in Charts Reviewed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cancer 
 
% of the types of cancer 
n = 301 
Myelodysplastic Syndrome 40% 
 
Hodgkin’s Lymphoma 26% 
 
Non Hodgkin’s Lymphoma  22% 
 
Leukemia 11% 
 
Multiple Myeloma 1% 
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Table 2 
Indicators documented in more than 50% of the charts at 12 and 24 months 
x
2
 = 0.51    p = 0.48   
 
 Serum Blood Urea Nitrogen and 
Creatinine 
 
Total 
No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
103 
26.8% 
282 
73.2% 
385 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
106 
28.8% 
262 
71.2% 
368 
100.0% 
x
2
 = 0.40    p = 0.53   
 
 Liver Function Tests  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
110 
28.6% 
275 
71.4% 
385 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
112 
30.4% 
256 
69.6% 
368 
100.0% 
x
2
 = 0.31    p = 0.58 
 
 
 
 
 
 
 
 Aggressive Management of Blood 
Pressure 
 
Total 
No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors  
152 
39.8% 
230 
60.2% 
382 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors  
155 
42.3% 
211 
57.7% 
366 
100.0% 
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Table 3:  
Indicators documented in more that 50% of charts at 12 months, but in less than 50% at 24 months 
 Consider Herpes Simplex Virus & 
Antifungal Prophylaxis 
 
 
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
49 
39.8% 
74 
60.2% 
123 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
60 
56.6% 
46 
43.4% 
106 
100.0% 
x
2
 = 6.42    p = 0.01 
 
 
 Pneumocystis Carinii Pneumonia 
Prophylaxis 
 
Total 
No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
47 
39.5% 
72 
60.5% 
119 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
55 
53.9% 
47 
46.1% 
102 
100.0% 
x
2 
= 4.60    p =0.03 
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Table 4 
 Blood and Urine Tests 
 Cytomegalovirus  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
67 
52.3% 
61 
47.7% 
128 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
65 
57.0% 
49 
43.0% 
114 
100.0% 
x
2
 = 0.53    p = 0.47 
 
 Female Sex Hormone Levels  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
151 
96.2% 
6 
3.8% 
157 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
145 
96.0% 
6 
4.0% 
151 
100.0% 
x
2
 = 0.05    p = 0.95  
 
 Male Sex Hormone Levels  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
106 
74.6% 
36 
25.4% 
142 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
107 
82.3% 
23 
17.7% 
130 
100.0% 
x
2
 = 2.34    p = 0.13 
 
 Serum Ferritin  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
358 
93.0% 
27 
7.0% 
385 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
334 
90.8% 
34 
9.2% 
368 
100.0% 
x
2
 = 1.25    p = 0.26 
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 Thyroid Function  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
290 
75.5% 
94 
24.5% 
384 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
275 
75.1% 
91 
24.9% 
366 
100.0% 
x
2
 = 0.02    p = 0.90 
 
 
 Urine Protein  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
284 
74.0% 
100 
26.0% 
384 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
283 
76.9% 
85 
23.1% 
368 
100.0% 
x
2
 = 0.88    p = 0.35 
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Table 5 
 Imaging Tests 
 Bone Density  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
107 
89.2% 
13 
10.8% 
120 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
101 
90.2% 
11 
9.8% 
112 
100.0% 
x
2
 = 0.06    p = 0.80 
 
 Chest Radiograph  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
283 
73.7% 
101 
26.3% 
384 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
295 
79.9% 
74 
20.1% 
369 
100.0% 
x
2
 = 4.12    p = 0.04 
 
 Mammogram  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
131 
94.2% 
8 
5.8% 
139 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
127 
94.1% 
8 
5.9% 
135 
100.0% 
x
2
 = 0.004    p = 0.95 
  
 Pulmonary Function Test  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
157 
76.6% 
48 
23.4% 
205 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
156 
80.8% 
37 
19.2% 
193 
100.0% 
x
2
 = 1.07    p = 0.30 
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Table 6 
 Preventative Exams 
 Breast/Skin/Testes Self Exam  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
383 
99.5% 
2 
0.5% 
385 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
362 
98.4% 
6 
1.6% 
368 
100.0% 
x
2
 = 2.21    p = 0.14 
 Endocarditis Prophylaxis  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
100 
98.0% 
2 
2.0% 
102 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
89 
98.9% 
1 
1.1% 
90 
100.0% 
x
2
 = 0.22    p =0.64 
 Osteopenia Prophylaxis  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
107 
77.0% 
32 
23.0% 
139 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
99 
76.2% 
31 
23.8% 
130 
100.0% 
x
2
 = 0.03    p = 0.87 
 PAP Smear  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
146 
97.3% 
4 
2.7% 
150 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
142 
97.9% 
3 
2.1% 
145 
100.0% 
x
2
 = 0.15    p = 0.74 
 Regular Dental Exam  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
378 
98.2% 
7 
1.8% 
385 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
361 
98.1% 
7 
1.9% 
368 
100.0% 
x
2
 = 0.01    p = 0.93 
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Routine Vision Exam  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
363 
94.3% 
22 
5.7% 
385 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
349 
94.8% 
19 
5.2% 
368 
100.0% 
x
2
 = 0.11    p = 0.74 
 
 Schirmer Testing  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
17 
70.8% 
7 
29.2% 
24 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
15 
68.2% 
7 
31.8% 
22 
100.0% 
x
2
 = 0.04    p = 0.85 
 
 Screen for Steroid Myopathy  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
99 
83.2% 
20 
16.8% 
119 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
97 
87.4% 
14 
12.6% 
111 
100.0% 
x
2
 = 0.80    p = 0.37 
 
 Secondary Cancer Screenings  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
369 
96.1% 
15 
3.9% 
384 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
352 
95.9% 
15 
4.1% 
367 
100.0% 
x
2
 = 0.02    p = 0.90 
 
 Smoking Cessation  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
86 
67.7% 
41 
32.3% 
127 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
79 
65.8% 
41 
34.2% 
120 
100.0% 
x
2
 = 0.10    p = 0.75 
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 Vaccines  
Total No Yes 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
355 
92.4% 
29 
7.6% 
384 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
342 
93.2% 
25 
6.8% 
367 
00.0% 
x
2
 = 0.15    p = 0.70 
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Table 7 
 Psychosocial Follow-up 
 Emotional Health Counseling  
Total N Y 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
344 
89.4% 
41 
10.6% 
385 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
336 
91.3% 
32 
8.7% 
368 
100.0% 
x
2
 = 0.82    p = 0.37 
 
 Sexual Function Assessment  
Total N Y 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
380 
99.0% 
4 
1.0% 
384 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
364 
99.5% 
2 
0.5% 
366 
100.0% 
x
2
 = 0.60    p = 0.45 
 
 Support Groups  
Total N Y 
Time:  12 mos.     # HSCT Survivors 
                               % HSCT Survivors 
380 
98.7% 
5 
1.3% 
385 
100.0% 
Time:  24 mos.     # HSCT Survivors 
                               % HSCT Survivors 
364 
98.9% 
4 
1.1% 
368 
100.0% 
x
2
 = 0.07    p = 0.79 
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Figure 1:  Shared Care Model  
 
This is the shared care model which is the proposed theoretical model 
for following patients long-term after cancer treatment (Oeffinger and McCabe, 2006). 
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Figure 2:  Indicator Tracking Sheet 
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Figure 3: Best Practice List 
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Figure 4: Treatment Summary 
Diagnosis:  
Date of diagnosis: Age at diagnosis: Date therapy complete:  
Prognostic features: Cytogenetics: 
 
 
Summary of treatment:  
Treatment Center(s)  
 
 
Past Medical History 
Problem Ongoing Therapy 
  
Relapse(s)        Yes      No 
Date:   Site Therapy 
   
Secondary Malignancy  Yes     No 
Date Site Therapy 
   
   
Protocol(s) 
Acronym/Number Therapy and dates 
  
Chemotherapy       Yes             No 
Date(s) Drug Name  Route Total dose (mg/kg or mg/m2) 
    
Radiation               Yes            No 
Type Site Date Dose per 
fraction (Gy) 
Total Dose 
     
Surgery                 Yes             No 
Date Procedure Surgeon/Institute 
   
Transfusion History 
Transfusion Reaction Pre Medication 
  
  
Adverse Drug Reactions/Allergies    Yes                  No 
Drug Reaction 
  
  
Hematopoietic Stem Cell Transplant     Yes           No 
Date of transplant: Donor source (periph/marrow/UCB): 
Type (auto or allo): HLA Match: 
Conditioning Regimen:   ABO: 
Cell dose: Sex:  
Institution: BMT Physician:  
Graft versus Host Disease       Yes (chronic or acute)          No 
Organs Involved:   
Grade:        None         Limited (localized to skin and/or liver)    Extensive                  
Severity:    Mild   (signs and symptoms do not interfere with function) 
                  Moderate   (signs and symptoms interfere somewhat with function) 
                  Extensive   (limits function substantially despite appropriate therapy) 
GVHD Treatment Summary 
Drug Start Date Stop Date 
   
   
HSCT Complications/Late Effects      Yes          No 
Problem Dates Ongoing Therapy 
   
 
Figure 4: Treatment Summary 
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Figure 5:  Recommended Follow-Up for HSCT Survivors 
Recommended 
Screening/Prevention 
Six Months One Year Annually Date done 
Annual dental exam NA X X  
Annual eye exam  X X  
Blood pressure screening  X X X  
Bone density testing 
(patients with > 3 
months steroid use or 
calcineurin inhibitor 
use.)  Consider 
osteopenia prophylaxis  
NA X If previously 
abnormal 
 
BUN/Creatinine X X X  
Cardiovascular risk 
assessment  
NA X X 
 
 
Chest X-ray If previously 
abnormal 
If previously 
abnormal 
If previously 
abnormal 
 
CMV testing If chronic graft vs. 
host disease 
If chronic graft vs. 
host disease 
If chronic graft vs. 
host disease 
 
Encapsulated organism 
prophylaxis. Consider 
antifungal, HSV, PCP 
prophylaxis 
If chronic graft vs. 
host disease 
If chronic graft vs. 
host disease 
If chronic graft vs. 
host disease 
 
Endocarditis prophylaxis 
for dental procedures 
per AHA guidelines 
NA X X  
Gonadal function 
assessment 
NA X X  
Immunizations  NA X X  
Liver function test X X If previously 
abnormal 
 
Psychosocial and quality 
of life assessment; sexual 
function assessment 
X X X  
Pulmonary function 
testing 
NA X If previously 
abnormal 
 
Secondary cancer 
screenings: 
Breast/skin/testes self-
exam; Pap smear, 
mammogram for women 
> 40 
X X X  
Serum ferritin testing NA X If previously 
abnormal 
 
Smoking cessation X X X  
Thyroid function test NA X If previously 
abnormal 
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Figure 6:  Cancer Screening for Men (source) 
Cancer Screening for Men 
Cancer is a health problem that can often be cured or managed when it is found early. Here are guidelines 
to check for some common cancers that affect men. Screening is checking for a disease when there are no 
signs. All adults should have a cancer related checkup every 3 years between the ages of 20 to 39 and 
every year starting at 40.  
These guidelines are from the American Cancer Society. They are for people who are at normal risk. 
Some men have a higher risk for a certain kind of cancer. Higher risk may be due to family history, 
lifestyle or other factors. Each man should talk with her doctor about her risk factors.  
You can change some of your risk factors. For example, if you quit smoking you can change your risk for 
cancers of the lung, mouth, larynx (voice box), bladder and kidney. You cannot change other factors like 
your genes. In some cases you may be referred to see a Genetic Counselor for an evaluation. 
Here are some common types of cancers that affect women and some reasons that may cause a person to 
have a higher risk. Use this as a guide to talk to your doctor about your own health and screening needs. 
Note, we use the term doctor, but you may be seen by another type of health care professional for your 
screening.  
Prostate 
Risk Factors Screening for normal risk 
 Family history of prostate cancer 
 Being African American 
 Age (being older) 
 Eating a diet high in animal fat or high fat 
dairy products 
 Beginning at age 50 talk with your doctor 
about getting screened for prostate cancer.  
 If you have any risk factors you may need 
to begin screening between ages 40 to 45. 
Discuss this with your doctor.  
 The American Cancer Society 
recommends that at age 50, you have a 
yearly digital rectal exam and Prostate 
Specific Antigen (PSA) blood test 
 A PSA blood test should be done each year 
for men who have at least a 10 year life 
expectancy and for younger men who have 
higher risk.  
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Testicular 
Risk Factors Screening for normal risk 
 Usually found between the ages of 20 to 
54, but can affect men at any age  
 Risk is 4 times greater for white men than 
African American men 
 History of having undescended testicle(s)  
 History of cancer in one testicle 
 Family history of testicular cancer 
 The American Cancer Society recommends 
that men talk with their doctor about 
whether they should practice monthly 
testicular exam 
 You should examine your testicles 
monthly, especially if you are in a high risk 
group. Tell your doctor right away if you 
find a mass or a lump.  
 
Colon or Rectal 
Risk Factor  Screening for normal risk 
 Being over 50 years old 
 Being inactive and/or overweight 
 Diet high in red/processed meat 
 Diet low in fruits and vegetables 
 Smoking 
 Heavy alcohol use 
 Family history of colorectal cancer 
syndrome or adenomatus polyps 
 Type 2 diabetes 
 History of colon or rectal cancer, colorectal 
polyps, or chronic inflammatory bowel 
disease (Crohn‟s Disease) 
Starting at age 50, the following tests may be 
ordered by your doctor. Talk to your doctor 
about which test is best for you.  
 Yearly fecal occult blood test (FOBT) or 
fecal immunochemical test (FIT) using the 
multiple sample method 
 Flexible sigmoidoscopy 
 Colonoscopy every 10 years 
 Double contrast barium enema exam every 
5 years 
 CT colonography (virtual colonoscopy) 
every 5 years 
 
 
Lung 
Risk Factors Prevention 
 Smoking 
 Exposure to second hand smoke 
 Family or personal history of lung cancer 
 Exposure to cancer causing agents in the 
workplace or the environment (asbestos, 
fibers, radon, some chemicals, uranium, 
arsenic, vinyl chloride, diesel exhaust) 
 The best way to prevent lung cancer is to 
stop smoking or never start. At this time 
there is no good way to check for lung 
cancer. The American Cancer Society does 
not recommend routine screening. Clinical 
trials are searching for ways to check for 
lung cancer.  
 Smoking causes over 85% of lung cancers.  
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Skin 
Risk Factors Screening for normal risk 
 Ultraviolet light exposure (sunlight) 
 Fair skin (light colored skin) 
 Family history of melanoma 
 Severe sunburns before age 18 
 Use of tanning beds 
 Smoking 
 Some workplace (coal tar, pitch, creosote, 
arsenic, or radium) 
 Look for changes every month with your 
skin, freckles or moles 
 Skin exam during a regular health checkup 
 
 
The American Cancer Society, American Heart Association and the American Diabetes Association have 
joined together on this advice (source?). To lower your risks for cancer, heart (cardiovascular) disease and 
diabetes aim at these goals:  
 Get to a healthy weight and maintain it. 
 Be active – exercise at least 30 minutes 5 or more days a week 
 Eat at least 5 servings of vegetables and fruits every day 
 Don‟t smoke or use tobacco. Ask for help to quit 
 Limit your alcoholic beverages to 1 drink per day for women and 2 per day for men 
 
Here are some places you may check for more information:  
 JamesLine at 1-800-293-5066 or on the web at cancer.osu.edu 
 American Cancer Society at 1-800-ACS-2345 or on the web at http://www.cancer.org  
 The National Comprehensive Cancer Network at http://www.nccn.org 
 National Cancer Institute 1-800-4 CANCER (800-422-6237) or on the web at http://cancer.gov 
 
Other helpful Patient Education handouts: (source, James Nursing) 
 The ABCD‟s of Melanoma and Skin Self-Exam 
 Cancer Genetics Consultation 
 Colorectal Cancer Screening 
 Irritable Bowel Syndrome 
 How to Quit Smoking 
 Sun Safety Tips 
 Testicular Self Exam  
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Talk to your doctor or others on your health care team if you have questions. You may request more 
written information from the Library for Health Information at (614) 293-3707 or email: health-
info@osu.edu.  
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Figure 7:  Cancer Screening for Women (source) 
Cancer Screening for Women 
Cancer is a health problem that can often be cured or managed when it is found early. Here are guidelines 
to check for some common cancers that affect women. Screening is checking for a disease when there are 
no signs. All adults should have a cancer related checkup every 3 years between the ages of 20 to 39 and 
every year starting at 40.  
These guidelines are from the American Cancer Society. They are for people who are at normal risk. 
Some women have a higher risk for a certain kind of cancer. Higher risk may be due to family history, 
lifestyle or other factors. Each woman should talk with her doctor about her risk factors.  
You can change some of your risk factors. For example, if you quit smoking you can change your risk for 
cancers of the lung, mouth, larynx (voice box), bladder and kidney. You cannot change other factors like 
your genes. In some cases you may be referred to see a Genetic Counselor for an evaluation. 
Here are some common types of cancers that affect women and some reasons that may cause a person to 
have a higher risk. Use this as a guide to talk to your doctor about your own health and screening needs. 
Note, we use the term doctor, but you may be seen by another type of health care professional for your 
screening.  
Breast 
Risk Factors Screening for normal risk 
 Being female 
 Age (being older) 
 Family or a personal history of breast or 
ovarian cancer 
 Having no children, or first child after age 
30 
 Period (menstruation) started before age 12 
or stopped after age 55 
 History of abnormal breast changes or 
dense breast tissue 
 Being inactive and/or overweight after 
menopause 
 Drinking 1 or more alcoholic beverages a 
day 
 Estrogen therapy – long-term oral 
contraceptives (birth control pills) or 
hormone therapy after menopause 
Between the ages of 20 to 40 a woman should:  
 Be familiar with how breasts normally feel 
and report any changes right away. Talk to 
your doctor about how to do a monthly 
breast self exam (BSE) 
 Women in their 20s and 30s should have a 
breast exam by their doctor at least every 3 
years. After age 40, women should have a 
breast exam done by a doctor every year.  
 
Age 40 and over a woman should:  
 Report any changes you notice in your 
breasts 
 Have your doctor examine your breasts 
every year 
 Have a mammogram every year 
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Cervical 
Risk Factors Screening for normal risk 
 A human papillomavirus (HPV) infection 
is the most common risk factor. HPV is 
passed from person to person by sexual 
contact. You are at risk if you have:  
 Sexual contact, especially at a 
young age (before 17) 
 A high number of sexual partners; 
or partners who had sex with many 
others 
 Eating a diet low in fruits and vegetables 
 Mother took DES (diethylstilbestrol) while 
pregnant 
 Family history of cervical cancer 
 Smoking 
 Being overweight 
 Estrogen therapy –long-term oral 
contraceptives (birth control pills) 
 Chlamydia infection 
 Multiple pregnancies  
 You should begin having Pap tests after 
becoming sexually active (vaginal 
intercourse). All women should have a Pap 
test by age 21. There are 2 kinds of Pap 
tests – one is done yearly, the other is done 
every two years. 
 At age 30, if you have 3 normal Pap tests 
in a row, your doctor may suggest that you 
be screened every 2 to 3 years. You may 
need a Pap test more often due to your 
health history (if you had abnormal Pap 
tests, STD‟s, genital warts or a weakened 
immune system. 
 A woman over age 70 may choose to stop 
having cervical cancer screening after at 
least 3 normal Pap tests in a row and no 
abnormal tests in 10 years.  
 Screening after a total hysterectomy if 
cervix is removed is usually not needed 
except if the surgery was done due to 
cancer or pre-cancer.  
 Talk to your doctor before you stop getting 
Pap tests 
 
Colon or Rectal 
Risk Factor  Screening for normal risk 
 Over 50 years old 
 Being inactive and/or overweight 
 Diet high in red/processed meat 
 Diet low in fruits and vegetables 
 Smoking 
 Heavy alcohol use 
 Family history of colorectal cancer 
syndrome or adenomatus polyps 
 Type 2 diabetes 
 History of colon or rectal cancer, colorectal 
polyps, or chronic inflammatory bowel 
disease (Crohn‟s Disease) 
Starting at age 50, the following tests may be 
ordered by your doctor. Talk to your doctor 
about which test is best for you.  
 Yearly fecal occult blood test (FOBT) or 
fecal immunochemical test (FIT) using the 
multiple sample method 
 Flexible sigmoidoscopy 
 Colonoscopy every 10 years 
 Double contrast barium enema exam every 
5 years 
 CT colonography (virtual colonoscopy) 
every 5 years 
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Endometrial (Lining of the Uterus or Womb) 
Risk Factors Screening for normal risk 
 Being overweight 
 Eating foods high in animal fats 
 Family history or endometrial cancer 
 Personal history of breast or ovarian cancer 
 Having infertility or never had a baby 
 Period (menstruation) began before age 12 
and stopped after age 50 
 Having taken Tamoxifen or long-term 
estrogen replacement therapy without 
progesterone (if you still have a uterus) 
 Personal or family history of a genetic 
colon cancer syndrome 
 At present there are not screening tests that 
are reliable to detect most endometrial 
cancers in a woman who has no symptoms 
 Report abnormal spotting, bleeding or 
pelvic pain to your doctor or gynecology 
professional 
 For women at high risk of Hereditary Non-
Polyposis Colon Cancer annual screening 
with endometrial biopsy may be offered 
beginning at age 35.  
 
Lung 
Risk Factors Prevention 
 Smoking 
 Exposure to second hand smoke 
 Family or personal history of lung cancer 
 Exposure to cancer causing agents in the 
workplace or the environment (asbestos, 
fibers, radon, some chemicals, uranium, 
arsenic, vinyl chloride, diesel exhaust) 
 The best way to prevent lung cancer is to 
stop smoking or never start. At this time 
there is no good way to check for lung 
cancer. The American Cancer Society does 
not recommend routine screening. Clinical 
trials are searching for ways to check for 
lung cancer.  
 Smoking causes over 85% of lung cancers.  
  
Skin 
Risk Factors Screening for normal risk 
 Ultraviolet light exposure (sunlight) 
 Fair skin (light colored skin) 
 Family history of melanoma 
 Severe sunburns before age 18 
 Use of tanning beds 
 Smoking 
 Some workplace (coal tar, pitch, creosote, 
arsenic, or radium) 
 Look for changes every month with your 
skin, freckles or moles 
 Skin exam during a regular health checkup 
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The American Cancer Society, American Heart Association and the American Diabetes Association have 
joined together on this advice. To lower your risks for cancer, heart (cardiovascular) disease and diabetes 
aim at these goals:  
 Get to a healthy weight and maintain it. 
 Be active – exercise at least 30 minutes 5 or more days a week 
 Eat at least 5 servings of vegetables and fruits every day 
 Don‟t smoke or use tobacco. Ask for help to quit 
 Limit your alcoholic beverages to 1 drink per day for women and 2 per day for men 
 
Here are some places you may check for more information:  
 JamesLine at 1-800-293-5066 or on the web at cancer.osu.edu 
 American Cancer Society at 1-800-ACS-2345 or on the web at http://www.cancer.org  
 The National Comprehensive Cancer Network at http://www.nccn.org 
 National Cancer Institute 1-800-4 CANCER (800-422-6237) or on the web at http://cancer.gov 
 
Other helpful Patient Education handouts:  
 The ABCD‟s of Melanoma and Skin Self-Exam 
 Cancer Genetics Consultation 
 Colorectal Cancer Screening 
 Endometrial Biopsy 
 Having a Female Pelvic Exam 
 Your Pap Smear Test 
 Irritable Bowel Syndrome 
 Laser Treatment for Gynecology 
 Questions and Answers About Having a Mammogram 
 How to Quit Smoking 
 Sun Safety Tips 
 
Talk to your doctor or others on your health care team if you have questions. You may request more 
written information from the Library for Health Information at (614) 293-3707 or email: health-
info@osu.edu.  
 
 
